<span item_type="fundamental" item_id="05f394344cca0a9e1cca8e2f32f4a2ca" counter_id="ST/US/NAMSW" env="prod"></span><span item_type="announcement" item_id="513805935602696321" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 2.978 M.</p><p>EPS: As of FY2025 Q1, the actual value is USD -0.34.</p><p></p><h3>Segment Revenue</h3><ul><li>Revenue for the three months ended March 31, 2025 was $2.978 million, compared to $1.401 million for the same period in 2024, an increase of $1.577 million or 113%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000095017025066413/nams-20250331.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Research and development expenses for the three months ended March 31, 2025 were $44.751 million, compared to $42.430 million for the same period in 2024, an increase of $2.321 million or 5%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000095017025066413/nams-20250331.htm"></span></li><li>Selling, general and administrative expenses for the three months ended March 31, 2025 were $27.152 million, compared to $14.453 million for the same period in 2024, an increase of $12.699 million or 88%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000095017025066413/nams-20250331.htm"></span></li><li>Operating loss for the three months ended March 31, 2025 was - $68.925 million, compared to - $55.482 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000095017025066413/nams-20250331.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the three months ended March 31, 2025 was - $36.468 million, compared to - $54.602 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000095017025066413/nams-20250331.htm"></span></li><li>Net cash provided by financing activities for the three months ended March 31, 2025 was $6.519 million, compared to $198.180 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000095017025066413/nams-20250331.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Fair value change - earnout was a gain of $3.992 million for the three months ended March 31, 2025, compared to a loss of - $8.702 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000095017025066413/nams-20250331.htm"></span></li><li>Fair value change - warrants was a gain of $13.762 million for the three months ended March 31, 2025, compared to a loss of - $30.248 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000095017025066413/nams-20250331.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li>The company plans to develop and commercialize obicetrapib for patients with ASCVD and/or HeFH and elevated levels of LDL-C despite being treated with currently available optimal lipid-lowering therapy.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000095017025066413/nams-20250331.htm"></span></li><li>NewAmsterdam Pharma has partnered with Menarini for the commercialization of obicetrapib in the majority of European countries, if approved, and plans to pursue development and commercialization in the United States independently.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000095017025066413/nams-20250331.htm"></span></li><li>The company is evaluating potential acquisition or license of new product candidates.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000095017025066413/nams-20250331.htm"></span></li></ul>

Newamsterdam Pharma - CW27 | 10-Q: FY2025 Q1 Revenue: USD 2.978 M